The Pipeline

3 Cheers for a Cartherics Board Member

Bryan Williams ranked among the world’s most prominent scientists

By Leigh Dayton, 16 June 2022

Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.

In the recently released edition its […]

2022-06-16T09:19:26+10:00June 16th, 2022|

She’s an Adventurer, Advocate, Author and a Cancer Survivor

Now Heather Hawkins is a member of the Cartherics Board

By Leigh Dayton  9 June 2022

It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.

“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]

2022-06-09T14:44:04+10:00June 9th, 2022|

Presentation: Multi-Functional Cell Therapies Summit

Chief Development Officer, Dr Nicholas Boyd

Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.

On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]

2022-01-27T16:58:33+11:00January 27th, 2022|

The Right Time & The Right Place

Cartherics welcomes a new Senior Research Fellow who says she has finally found The Right Job

By Leigh Dayton, 20 January 2022

Pollyanna Goh – Polly to her friends, family and colleagues – is a specialist’s specialist. For the past decade she has worked in the field of induced pluripotent stem cells (iPSCs). She was such an […]

2022-01-20T10:36:47+11:00January 20th, 2022|

‘Off-the-Shelf’ Immunotherapy Gets Special Treatment in Special Issue of The Journal Cells

Thanks go to Special Editor, Cartherics CEO Alan Trounson

By Leigh Dayton, 17 January 2022

Cellular immunotherapy is revolutionizing cancer treatment, and off-the-shelf or allogeneic, treatments are beginning to replace technologies developed individually for each patient.

This is good news because the potential of allogeneic therapies is great. They promise to significantly save time and cut costs compared […]

2022-01-17T09:29:18+11:00January 17th, 2022|

A Star is Born! Cartherics student takes out top award …..

By Leigh Dayton,  4 January 2022

When Cartherics Biomedical Honours student Elizabeth (Liz) Bakaniozos opened an e-mail this month from the Director and CEO of Monash University’s Hudson Institute of Medical Research she was “really surprised and grateful”.

And rightly so. Elizabeth Hartland wrote to advise and congratulate Liz on winning the Hudson Institute Lois Salamonsen Honours […]

2022-01-04T12:17:29+11:00January 4th, 2022|

Three Cheers for the CARTeam!

By Leigh Dayton, 6 December 2021

When eight Cartherics women first teamed-up to walk or run 4km every day in November and raise funds to support women living with ovarian cancer, they set what they believed were achievable goals. The newly minted CARTeam would collectively move 120 km and raise $500.

They sorely misjudged their efforts. Despite […]

2021-12-06T20:42:53+11:00December 6th, 2021|

Go CARTeam Go ! update from the halfway mark …….

Ovarian Cancer Australia set the challenge and Cartherics accepted in winning style

By Leigh Dayton 22 November 2021

It was a challenge that had to be met.  “This November, walk or run 4km every day and raise funds to support women living with ovarian cancer,” proposed Ovarian Cancer Australia (OCA), a not-for-profit organisation which supports women […]

2021-11-23T13:12:01+11:00November 23rd, 2021|

‘Off-the-Shelf’ Immunotherapy: Manufacture of Cancer-Killing Cells from Donor Cells

‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells

Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.

In this […]

2021-10-08T13:43:35+11:00October 8th, 2021|

Cartherics CEO contributes his expertise

Alan Trounson joins regenerative medicine advisory committee

By Leigh Dayton

7 October 2021

According to Cartherics CEO Alan Trounson, taking ideas from the laboratory to the marketplace is a “long and tortuous process”. First-hand experience goes far towards identifying and navigating the hurdles of research translation.

And experience – from pioneering work in IVF and embryonic stem cell science […]

2021-10-07T09:43:41+11:00October 7th, 2021|
Go to Top